Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 5/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160935 | 0.89 | AKR1C3 (0.34) | — | |
| SCHEMBL5160713 | 0.82 | RAB9A (0.37) | RAB9ANPC1 | |
| SCHEMBL510966 | 0.79 | — | — | |
| SCHEMBL2367546 | 0.76 | — | — | |
| SCHEMBL10410365 | 0.74 | BRD4 (0.39) | RAB9ANPC1 | |
| SCHEMBL867773 | 0.74 | — | — | |
| SCHEMBL532337 | 0.72 | — | — | |
| SCHEMBL18358128 | 0.70 | — | — | |
| SCHEMBL7914616 | 0.70 | — | — | |
| SCHEMBL583977 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 665 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12638614-B2 | Method for making silicone hydrogel contact lenses | ALCON INC. (CH) | 2026-05-26 | — | — | US | claimed |
| US-20260131506-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2026-05-14 | — | — | US | claimed |
| US-12595368-B2 | UV/HEVL-filtering contact lenses | ALCON INC. (CH) | 2026-04-07 | — | — | US | claimed |
| EP-4713721-A1 | UV/HEVL-FILTERING SILICONE HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2026-03-25 | — | — | EP | claimed |
| US-12570784-B2 | Method for making embedded hydrogel contact lenses | ALCON INC. (CH) | 2026-03-10 | — | — | US | claimed |
| EP-3759528-B1 | SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2026-03-04 | — | — | EP | claimed |
| EP-4514596-B1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2026-03-04 | — | — | EP | claimed |
| US-12539650-B2 | Method for making embedded hydrogel contact lenses | ALCON INC. (CH) | 2026-02-03 | — | — | US | claimed |
| US-20250347826-A1 | METHOD FOR PRODUCING WETTABLE SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2025-11-13 | — | — | US | claimed |
| US-20250340028-A1 | CONTACT LENSES WITH SOFTER LENS SURFACES | ALCON INC (CH) | 2025-11-06 | — | — | US | claimed |
| US-20040067365-A1 | LbL-coated medical device and method for making the same | ALCON INC. (CH) | 2004-04-08 | — | — | US | claimed |
| WO-2004024203-A1 | LBL-COATED MEDICAL DEVICE AND METHOD FOR MAKING THE SAME | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | claimed |
| US-6558688-B2 | Ocular tissue regeneration inducer | KURARAY CO., LTD. (JP) | 2003-05-06 | — | — | US | claimed |
| US-20010038860-A1 | Ocular tissue regeneration inducer | KURARAY CO., LTD.; (JP) | 2001-11-08 | — | — | US | claimed |
| CN-1283280-A | Actively controllable multifocal lens | NOVARTIS AG (CH) | 2001-02-07 | — | — | CN | claimed |
| EP-1044389-A2 | ACTIVELY CONTROLLABLE MULTIFOCAL LENS | Novartis AG (CH) | 2000-10-18 | — | — | EP | claimed |
| US-5997140-A | Actively controllable multifocal lens | NOVARTIS AG (CH) | 1999-12-07 | — | — | US | claimed |
| WO-1999034239-A2 | ACTIVELY CONTROLLABLE MULTIFOCAL LENS | NOVARTIS AG (CH) | 1999-07-08 | — | — | WO | claimed |
| US-4123408-A | Hydrogel contact lens | AMERICAN OPTICAL CORPORATION (US) | 1978-10-31 | — | — | US | claimed |
| US-4123407-A | Hydrophilic contact lens | AMERICAN OPTICAL CORPORATION (US) | 1978-10-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539650-B2 | Method for making embedded hydrogel contact lenses | INF2, CRYZ, CRYAA | PER2 1301/4885RAB9A 4673/4885NPC1 4717/4885 |
| US-12595368-B2 | UV/HEVL-filtering contact lenses | UACA, HSPA4L, RAD54L | PER2 604/4885RAB9A 4835/4885NPC1 3998/4885 |
| US-12570784-B2 | Method for making embedded hydrogel contact lenses | CRYAB, CRYZ, CRYAA | PER2 732/4885RAB9A 3508/4885NPC1 3173/4885 |
| US-12638614-B2 | Method for making silicone hydrogel contact lenses | SMCHD1, CRYAA, CRYZ | PER2 877/4885RAB9A 4110/4885NPC1 4772/4885 |
| US-20260131506-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | CRYZ, CRYAB, CRYAA | PER2 394/4885RAB9A 4338/4885NPC1 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.